plerixafor has been researched along with Thrombopenia in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Bhattarai, G; Cho, ES; Kim, MH; Kook, SH; Lee, JC; Poudel, SB; Sim, HJ; So, HS | 1 |
Calandra, G; Gandhi, PJ; Jacobsen, ED; Micallef, IN; Shaughnessy, P; Uberti, J; van Rhee, F | 1 |
2 other study(ies) available for plerixafor and Thrombopenia
Article | Year |
---|---|
Local and Systemic Overexpression of COMP-Ang1 Induces Ang1/Tie2-Related Thrombocytopenia and SDF-1/CXCR4-Dependent Anemia.
Topics: Anemia; Angiopoietin-1; Animals; Cartilage Oligomeric Matrix Protein; Chemokine CXCL12; Mice; Mice, Transgenic; Receptor, TIE-2; Thrombocytopenia | 2023 |
G-CSF plus plerixafor (Mozobil) to mobilize hematopoietic stem cells in patients with thrombocytopenia or leukopenia prior to auto-SCT.
Topics: Benzylamines; Blood Component Removal; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Leukocyte Count; Leukopenia; Lymphoma, Non-Hodgkin; Multiple Myeloma; Platelet Count; Retrospective Studies; Thrombocytopenia | 2013 |